Rocket Pharmaceuticals, Inc.

What they do

Rocket develops and manufactures AAV-based gene therapies for rare, often fatal diseases. Its lead approved product, KRESLADI, treats pediatric severe LAD-I patients with biallelic ITGB2 mutations lacking a suitable HLA-matched sibling donor. The company also advances clinical programs for Danon disease (RP-A501), PKP2-ACM (RP-A601), and BAG3-DCM (RP-A701), supported by an in-house cGMP manufacturing facility in Cranbury, New Jersey.

Revenue drivers

• KRESLADI (LAD-I gene therapy) — FDA-approved product; ultra-rare pediatric population; no material revenue expected in the near term; commercial launch preparations underway with patient onboarding beginning Q4 2026.
• RP-A501 (Danon disease) — Phase 2 pivotal trial; no revenue yet; potential future BLA submission; represents a major cardiovascular program.
• RP-A601 (PKP2-ACM) and RP-A701 (BAG3-DCM) — Earlier-stage cardiovascular programs; no revenue; potential pivotal trials and future commercialization.

Recent performance

For Q2 2026, Rocket reported zero revenue and a net loss; the company had cash and investments of approximately $283.7 million as of June 30, 2026, with cash runway into Q2 2028. The company completed a $180 million sale of its Rare Pediatric Disease Priority Review Voucher in Q2 2026, providing non-dilutive capital. Annual net loss for 2025 was $-223.1 million, with operating cash outflow of $-190.0 million. No product sales have been generated to date.

Strategy

Management is focusing on a rare cardiovascular gene therapy platform, prioritizing RP-A501, RP-A601, and RP-A701. The company de-prioritized FA and PKD programs as part of a July 2025 reorganization that cut workforce by 30% and is expected to reduce 12-month operating expenses by 25%. Commercial efforts for KRESLADI are scaled to the ultra-rare patient population. The company also plans to evaluate strategic partnerships for non-core programs and pursue FDA priority review vouchers if Congress renews the program.

Risks

• Regulatory delays — RP-A501 clinical hold was lifted but FDA alignment is still needed to complete the pivotal Phase 2 trial; regulatory update expected in H2 2026.
• No revenue history — No products approved for sale until KRESLADI's recent approval; no material revenue expected near term, so sustained losses and negative cash flow persist.
• Commercial execution risk — KRESLADI targets an exceptionally small patient population, making revenue ramp and reimbursement uncertain.
• Pipeline concentration — De-prioritization of FA and PKD programs increases reliance on cardiovascular programs, which are still in clinical development and may fail.

Outlook

Management expects to provide a Danon disease program update and regulatory pathway update in H2 2026, including an investor webinar. They anticipate a regulatory update for the planned RP-A601 pivotal study and initial patient dosing with RP-A701 in BAG3-DCM in H2 2026. KRESLADI commercial availability and patient onboarding are expected to begin in Q4 2026, with no material near-term revenue expected. Cash runway is projected into Q2 2028.